Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer.

Kim HM, Lee KJ, Cha J, Chung MJ, Bang S, Seong J, Song SY, Park SW.

Cancer Chemother Pharmacol. 2014 Oct;74(4):861-5. doi: 10.1007/s00280-014-2565-y. Epub 2014 Aug 17.

PMID:
25129491
2.

A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer.

Lee KJ, Yi SW, Cha J, Seong J, Bang S, Song SY, Kim HM, Park SW.

Cancer Chemother Pharmacol. 2016 Oct;78(4):841-6. doi: 10.1007/s00280-016-3143-2. Epub 2016 Sep 1.

PMID:
27586966
3.

Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.

Kim HS, Kim HY, Zang DY, Oh HS, Jeon JY, Cho JW, Park CK, Kim JH, Kim MJ, Ha HI, Kim JH, Han B, Song H, Kwon JH, Choi DR, Jung JY.

Cancer Chemother Pharmacol. 2015 Apr;75(4):711-8. doi: 10.1007/s00280-015-2687-x. Epub 2015 Jan 29.

PMID:
25630414
4.

Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.

Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O, Toda N, Yasuda I, Hasebe O, Maetani I, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M.

Cancer Chemother Pharmacol. 2010 May;65(6):1101-7. doi: 10.1007/s00280-009-1115-5. Epub 2009 Aug 26.

PMID:
19707761
5.

A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.

Kanai M, Yoshimura K, Tsumura T, Asada M, Suzuki C, Niimi M, Matsumoto S, Nishimura T, Nitta T, Yasuchika K, Taura K, Mori Y, Hamada A, Inoue N, Tada S, Yanagihara K, Yazumi S, Osaki Y, Chiba T, Ikai I, Fukushima M, Uemoto S, Hatano E.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1429-34. doi: 10.1007/s00280-010-1443-5. Epub 2010 Sep 2.

6.

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.

Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, Boku N, Yanagimoto H, Sato T, Furuse J.

Cancer Chemother Pharmacol. 2013 May;71(5):1141-6. doi: 10.1007/s00280-013-2106-0. Epub 2013 Mar 24.

7.

A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.

Arima S, Shimizu K, Okamoto T, Toki M, Suzuki Y, Okano N, Naruge D, Kawai K, Kobayashi T, Kasuga A, Kitamura H, Takasu A, Nagashima F, Sugiyama M, Furuse J.

Anticancer Res. 2017 Feb;37(2):909-914.

PMID:
28179351
8.

A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.

Shinchi H, Maemura K, Mataki Y, Kurahara H, Sakoda M, Ueno S, Hiraki Y, Nakajo M, Natsugoe S, Takao S.

J Hepatobiliary Pancreat Sci. 2012 Mar;19(2):152-8. doi: 10.1007/s00534-011-0400-y.

PMID:
21647560
9.

Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.

Kaira K, Tomizawa Y, Yoshino R, Yoshii A, Matsuura M, Iwasaki Y, Koga Y, Ono A, Nishioka M, Kamide Y, Hisada T, Ishizuka T, Shirai K, Ebara T, Saitoh J, Nakano T, Sunaga N.

Lung Cancer. 2013 Dec;82(3):449-54. doi: 10.1016/j.lungcan.2013.09.004. Epub 2013 Sep 19.

PMID:
24099666
10.

A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.

Ikeda M, Ioka T, Ito Y, Yonemoto N, Nagase M, Yamao K, Miyakawa H, Ishii H, Furuse J, Sato K, Sato T, Okusaka T.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):163-9. doi: 10.1016/j.ijrobp.2012.03.059. Epub 2012 Jun 5.

PMID:
22677367
11.

Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.

Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK.

Cancer Chemother Pharmacol. 2007 Aug;60(3):321-8. Epub 2006 Dec 2.

PMID:
17143602
12.

Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.

Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H, Nakachi K, Ueno H, Ikeda M, Morizane C, Horikawa Y, Mizuno N.

Jpn J Clin Oncol. 2006 Sep;36(9):552-6. Epub 2006 Aug 3.

PMID:
16887837
13.

Phase II study of S-1 in patients with advanced biliary tract cancer.

Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C.

Br J Cancer. 2004 Nov 15;91(10):1769-74.

14.

A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.

Kim YJ, Im SA, Kim HG, Oh SY, Lee KW, Choi IS, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Kim SW, Heo DS, Yoon YB, Bang YJ.

Ann Oncol. 2008 Jan;19(1):99-103. Epub 2007 Sep 9.

PMID:
17846018
15.

Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.

Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Hara T, Denda T, Tawada K, Imagumbai T, Araki H, Sakai M, Hatano K, Kawakami H, Uno T, Ito H, Yokosuka O.

Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):119-25. doi: 10.1016/j.ijrobp.2010.01.027. Epub 2010 Jun 3.

PMID:
20605363
16.

Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).

Kanai M, Hatano E, Kobayashi S, Fujiwara Y, Sakai D, Kodama Y, Ajiki T, Nagano H, Ioka T.

Cancer Chemother Pharmacol. 2012 May;69(5):1181-8. doi: 10.1007/s00280-011-1818-2. Epub 2012 Jan 12.

PMID:
22237958
17.

A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.

Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T.

Cancer Chemother Pharmacol. 2009 Dec;65(1):113-20. doi: 10.1007/s00280-009-1011-z. Epub 2009 Apr 29.

PMID:
19404641
18.

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.

Kim KP, Jang G, Hong YS, Lim HS, Bae KS, Kim HS, Lee SS, Shin JG, Lee JL, Ryu MH, Chang HM, Kang YK, Kim TW.

Br J Cancer. 2011 Feb 15;104(4):605-12. doi: 10.1038/bjc.2011.17.

19.

S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study.

Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A.

Cancer Chemother Pharmacol. 2008 Oct;62(5):849-55. doi: 10.1007/s00280-007-0673-7. Epub 2008 Jan 23.

PMID:
18214482
20.

Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer.

Oh SY, Lee GW, Kim HG, Kim TH, Kim HJ, Kang JH.

Chemotherapy. 2008;54(6):479-84. doi: 10.1159/000159624. Epub 2008 Oct 3.

PMID:
18832821

Supplemental Content

Support Center